17. The composition of any one of claims 1 to 16, wherein the carrier matrix is colostrum.

18. The composition of claim 17, wherein the colostrum is non-hyperimmune bovine colostrum.

19. The composition of claim 17 or claim 18, wherein the colostrum is dried full-fat bovine colostrum.

~~19.~~20. The composition of any one of claims 1 to 19~~claims 1-18~~, wherein the specific binding molecule is in a solid form.

~~20.~~21. The composition of claim 20~~claim 19~~, wherein the specific binding molecule is crystalline.

~~21.~~22. The composition of any one of claims 1 to 21~~to 20~~, wherein the carrier matrix is in a solid form.

~~22.~~23. The composition of any one of claims 1 to 21 ~~to 20~~ further comprising a pharmaceutically acceptable diluent, binder, excipient, lubricant, sweetening agent, flavoring agent, wetting agent, or absorbent.

~~23.~~24. A method for preparing the composition of any one of claims 1 to 23~~to 22~~, comprising

(a) obtaining at least one specific binding molecule or fragment thereof from an animal that binds to a specific antigen, wherein the specific binding molecule is selected from an immunoglobulin, antibody, ~~peptide, cell receptor, variable lymphocyte receptor, transfer factor, and~~ or a mixture thereof;

(b) obtaining at least one carrier matrix, comprising at least two components

obtained from a nonhuman animal selected from the group consisting of enzymes, lactoferrin, transferrin, nonspecific immunoglobulins, cytokines, white blood cells, complement components, interferons, and fibronectin, wherein the carrier matrix comprises a matrix selected from the group consisting of, obtained from, isolated from, or derived from, serum, plasma, colostrum, or milk;

(c) preparing a solid form of the carrier matrix and of the specific binding molecule or fragment thereof ; and

(d) mixing the solid form of the carrier matrix with the solid form of the specific binding molecule or fragment thereof .

~~24.~~25. The method of claim 24~~claim 23~~, wherein the specific binding molecule or fragment thereof contains a non-neonate human effective amount of the specific binding molecule or fragment thereof.

~~25.~~26. The method of ~~claim 23 or~~ claim 24 or claim 25, wherein the matrix ~~comprises a matrix selected from the group consisting of~~ colostrum~~, milk, serum, plasma, saliva, lymph fluid, mucous fluid, and lachrymal fluid~~.

27. The method of any one of claims 24 to 26, wherein the matrix comprises a matrix consisting of non-hyperimmune bovine colostrum.

28. The method of claim 26 or claim 27 wherein the colostrum is full-fat bovine colostrum

~~26.~~29. The method of any one of claims 24 to 28~~23 to 25~~, wherein the at least two components of the carrier matrix are selected from the group consisting of lysozyme, phospholipase, defensins, opsonins, nonspecific immunoglobulins, proline-rich polypeptides (PRPs), components of the complement system, beta-lysin, lactoferrin, transferrin, cytokines, interleukins, chemokines, interferons, TNF-alpha, fibronectin, leukocytes, white blood cells,